Anti-VEGF Therapies May Lead to Sustained Intraocular Pressure Spikes
Presented at AAO, Chicago
The use of intravitreal injections of vascular endothelial growth factor inhibitors (anti-VEGF) to treat diseases such as age-related "wet" macular degeneration (AMD), may also put some patients at risk of elevated intraocular pressure (IOP) and therefore at risk of vision loss due to glaucoma. According to data presented here October 17 at the Annual Meeting of the American Academy of Ophthalmology (AAO), potentially dangerous increases in IOP have been seen in some patients who have had multiple injections of drugs such as bevacizumab and ranibizumab.
